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Aims:  Phosphodiesterase  4  (PDE4)  inhibitors  have
been  described  as  potent  anti-inflammatory  com-
pounds, involving an increase in intracellular levels
of cyclic 39 ,59 -adenosine monophosphate (AMP). The
aim  of  this  study  was  to  compare  the  effects  of
selective  PDE4  inhibitors,  rolipram  and  RP  73Ð401
with  the  cell  permeable  analogue  of  cyclic  AMP,
dibutyryl-cyclic  AMP (db-cAMP) and the anti-inflam-
matory cytokine interleukin-10 (IL-10) on superoxide
anion  production  from  peripheral  blood  mononu-
clear  cells  preincubated  with  lipopolysaccharide
(LPS).
Major findings: We report that, after incubation of the
cells with LPS, a large increase in superoxide anion
production  was  observed.  Rolipram  or  RP  73Ð401
(10Ð8 to  10Ð5 M)  induced  significant  reductions  of
fMLP-induced superoxide anion production  in  cells
incubated with or without LPS. The db-cAMP (10Ð5 to
10Ð3 M) also elicited dose-dependent inhibitions of the
fMLP-induced superoxide anion production. In con-
trast, IL-10 (1 or 10ng/ml) did not elicit a reduction in
fMLP-induced superoxide anion production in both
conditions.
Principal  conclusion: These results suggest  that  the
inhibitory  activity  of  PDE4  inhibitors  on  fMLP-
induced production of superoxide anion production
is mediated by db-cAMP rather than IL-10.
Key  words:  Cyclic  AMP,  Interleukin  10,  Lipopolysac-
charide,  Mononuclear  cells, Phosphodiesterase inhibitors,
TNF-a
Introduction
Increased intracellular levels of the nucleotide cyclic
39 ,59 -adenosine monophosphate (cyclic AMP) and the
subsequent activation of cyclic AMP-dependent pro-
tein  kinase  (PKA)  in  both  the  respiratory  smooth
muscle and inflammatory cells result in bronchodila-
tion, reduction of inflammation and immunomodula-
tory  activities.1 The  intracellular  concentration  of
cyclic  nucleotides  is  mainly  determined  by  the
activation of adenylyl cyclase coupled with adreno-
ceptor and G-protein, and by the breakdown of cyclic
nucleotide by phosphodiesterases (PDEs). PDEs are a
family of enzymes that hydrolyze the 39 -ribose phos-
phate bond of  the naturally occurring second mes-
senger  nucleotide  39 ,59 -cyclic  monophosphate  to
form biologically inert 59 -nucleotide monophosphate.
PDEs  are,  at  present,  divided  into  at  least  seven
families, each with distinct substrate specificities and
regulatory  characteristics.1 Among  these  families,
PDE3 and PDE4 are responsible for cAMP hydrolysis;
however, PDE4 is mainly present in the inflammatory
cells. Therefore, selective type  4  phosphodiesterase
inhibitors are able to elicit an increase in intracellular
cAMP content. Due to their potent anti-inflammatory
activity, the interest in selective PDE4 inhibitors in the
treatment of pulmonary inflammatory disorders has
been  greatly  increasing  for  the  past  few  years  (for
reviews, see References 2 and 3).
We previously demonstrated that PDE4 inhibitors
are  able  to  reduce  the  fMLP-induced  arachidonate
release  from  human  mononuclear  cells.4 Neverthe-
less, this release was not associated with an increase
in cyclic AMP in human mononuclear cells.4 Moreo-
ver,  PKA  inhibitors  did  not  reduce  the  inhibitory
activity of selective PDE4 inhibitors on arachidonate
and tumor necrosis factor-alpha (TNF-a ) release from
monocytes,5,6 suggesting that other mechanisms are
involved in the anti-inflammatory activity of selective
PDE4 inhibitors. Hence, the effect of PDE4 inhibitors
appeared to be partly mediated through the release of
the  anti-inflammatory  cytokine,  interleukin  10  (IL-
10),7,8 which controls the formation of pro-inflamma-
tory cytokine such as TNF-a .
The aim of this study was to compare the effects of
two  selective  PDE4  inhibitors  (rolipram  and  RP
73–401)  with  the  cell-permeable  analog  of  cyclic
AMP,  dibutyryl-cyclic AMP  (db-cAMP)  and  IL-10  on
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blood  mononuclear  cells  (PBMC)  preincubated  in
lipopolysaccharide  (LPS)  as  a  model  of  cellular
hyperreactivity.
Materials and methods
Preparation of PBMC
Mononuclear  cells  were  isolated  from  buffy  coats
(CRTS Rennes, France) obtained from healthy donors
by density gradient centrifugation (20min at 1100 ´ g)
on  Ficoll-Hypaque.  Cells  recovered at  the  interface
were  washed twice  with  phosphate-buffered  saline
without Ca2+ and Mg2+ (PBS). Mononuclear cells were
resuspended  in  RPMI  1640  supplemented  with
L-glutamine (2 mM), penicillin (100U/ml) and strepto-
mycin (100g/ml), and 10% heat-inactivated fetal calf
serum  (RPMI-FCS).  The  cells  were  counted  and
assessed for viability by Trypan blue exclusion. Under
these conditions, the viability of cells exceeded 95%.
Protocol and drug treatments
Cell  concentration was  adjusted  to  106 cells/ml  in
RPMI  containing  streptomycin  (10UI/ml),  glutamin
(2 m mol/ml) and penicillin (10 m g/ml). The cell  sus-
pensions were then placed at 4°C for 2h. After this
period, the cells were incubated with LPS (10 m g/ml)
or vehicle, for 30min at 37°C.
Then, the cells were incubated either with rolipram
(10–8, 10–7, 10–6 or 10–5 M) or RP 73–401 (10–8, 10–7,
10–6 or 10–5 M) or db-cAMP (10–5, 10–4 or 10–3 M) or IL-
10 (1 and 10ng/ml) or vehicle, for 30min at 37°C.
For  each  set  of  experiments,  n represents  the
number  of  subjects.  For  each  subject,  the  experi-
ments using cells treated or not with LPS were carried
out in triplicate.
Superoxide anion production
Immediately  after  the  compound  or  vehicle  treat-
ments, peaks of maximum luminol-dependent chem-
iluminescence technique (LDCL) (expressed in rela-
tive light units (RLU)) after fMLP stimulation (10–6 M)
were  measured  on a  Beckman counter  on  200000
cells in the presence of 700 m l of a luminol solution
(0.02mg/ml) (modified from Reference 9).
For kinetic study, cells were only incubated with
LPS or vehicle and RLU were measured every 30sec,
1.5min  before  and  3.5min  after  FMLP  stimulation,
using repeated measures on the same set of experi-
ments of different subjects.
Statistical analysis
All results are expressed as means ± SEM. Statistical
differences  were  assessed  using  the  analysis  of
variance and Student’s t-test. P < 0.05 was accepted
as  being  significant.  For  the  kinetic  study,  the
curves  were  compared  using  two-way  analysis  of
variance.
Drugs and chemicals
The following drugs were used: Ficoll-Hypaque (Phar-
macia, Upsala, Sweden), PBS, RPMI 1640, glutamine,
penicillin  and streptomycin (Gibco, Cergy-Pontoise,
France), FCS  (Flow Laboratories, Irvine, UK), dime-
thysulfoxide  (DMSO), db-cAMP, 5-amino-2,3-dihydro-
1,4-phthalazinedione (luminol), N-formyl-Met-Leu-Phe
(fMLP)  and  LPS  from  Escherichia  coli (0.55  B5)
(Sigma, St. Louis, MO, USA), and IL-10 (R&D systems,
Minneapolis,  MN,  USA).  Luminol  solution  was
obtained from a basal solution of 2mg/ml in DMSO
stored at –20°C and dissolved in PBS buffer  before
LDCL experiments. Rolipram was a generous gift from
Dr J.M. Planquois  (Institut  de Recherche Jouveinal/
Parke-Davis, Fresnes,  France)  and  RP  73401  was  a
generous gift  from  Dr  J.J.  Bourguignon  (Facult´ e  de
Pharmacie, Illkirch, France). They were first dissolved
in  0.1%  DMSO  and  then  diluted  in  RPMI  supple-
mented  with  0.2%  fatty  acid  free  bovine  serum
albumin.  Vehicle  controls  were  included  in  the
experimental design.
Results
Time-course of the fMLP-induced LDCL
As shown in Figure 1, there is no change in the LDCL
between  LPS-treated  or  control  cells  before  the
stimulation with  fMLP. After  1.5min  of stable basal
level in LDCL, the cells were stimulated with 1 m M of
fMLP and a marked increase in the production of RLU
was noted. However, after incubation of the cells with
LPS,  a  large  increase  in  LDCL  was  observed  in
comparison with control (non-treated cells) (Fig. 1).
The maximum LDCL was observed at 3min after the
beginning  of  the  experiment,  i.e.  1.5min  after  the
stimulation with fMLP, whether or not the cells were
treated with LPS.
Addition of superoxide dismutase (100 or 300IU)
to fMLP-stimulated cells induced a 50 and 90% LDCL
decrease, respectively, whether or not the cells were
treated  with  LPS  (data  not  shown).  This  result
demonstrates  that  most  reactive  oxygen  species
released  from  cells  and  measured  by  LDCL  are
superoxide anions.
Effects of rolipram and RP 73–401 on
superoxide anion production from PBMC
When the cells were incubated with rolipram (10–8
to 10–5 M) or RP 73–401 (10–8 to 10–5 M), a reduc-
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was  observed  (Fig.  2).  Maximal  inhibitions  were
observed  at  10–6 M  rolipram  and  10–7 M  RP
73–401.
After stimulation of the cells with LPS, the super-
oxide anion production induced by fMLP was mark-
edly  enhanced.  In  this  condition,  rolipram  and  RP
73–401 also elicited reduction of superoxide anion
production  (Fig.  2).  These  inhibitory  effects  were
significant  from  10–7 M  rolipram  and  10–8 M  RP
73–401,  and maximal  inhibitions were observed at
these concentrations.
Effects of db-cAMP on superoxide anion
production from PBMC
When the cells were incubated with db-cAMP, a dose-
dependent inhibition of the fMLP-induced superoxide
anion  production  was  also  observed  (Fig.  3). This
inhibitory effect was similar whether the cells were
incubated or not with LPS, since the effect appeared
significantly from 10–4 M db-cAMP.
Effects of IL-10 on superoxide anion production
from PBMC
Incubation of  PBMC with IL-10  (1  or 10ng/ml)  for
30min  did  not  elicit  a  reduction  in  fMLP-induced
superoxide  anion  production,  whether  or  not  the
cells were treated with LPS (Fig. 4).
Discussion
The major finding of this study was that the selective
PDE4 inhibitors rolipram and RP 73–401, as well as
the PKA activator db-cAMP, but not IL-10, were able to
reduce the much enhanced superoxide anion produc-
tion of PBMC primed with LPS and thus stimulated
with fMLP.
In  the  present  study,  we  presented  an  in  vitro
model  of  enhanced reactivity  of  the  human  PBMC
following  incubation  with  LPS.  This  enhanced
response is observed using  the chemiluminescence
technique  that  is  mainly  stimulated  by  superoxide
production under  the  stimulation of the  cells with
fMLP.
Lipopolysaccharides  are  potent  and  pleiotropic
stimuli for cells of the immune system. Stimulation of
leucocytes by LPS leads to the release of  cytokines
and  inflammatory  mediators  that  enhance  host
defense  against  microorganisms.10 Priming  is  con-
sidered to result from exposure to a low concentra-
tion of an agent, which itself has little or no effect on
function but that allows a second agent to provoke a
response  that  is  larger  than  the  non-primed
response.11 Such  a  priming  has  been  previously
observed for  the  release  of  5-lipoxygenase  metabo-
lites from PBMC.12
The mechanism of  LPS-dependent priming is not
completely understood. However, it has been repor-
ted that TNF-a released from  monocytes stimulated
with  endotoxin  is  a  potent  primer  of  oxidative
activity.13 Regarding  the  superoxide  anion  produc-
PDE4 inhibitors and superoxide anion
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FIG. 1. Time-course of the superoxide anion production from human peripheral blood mononuclear cells in the absence
(control) or presence of lipopolysaccharide (LPS) (10m g/ml for 30min). Superoxide anion production was measured by the
luminol-dependent chemiluminescence technique (expressed in relative light units (RLU)). Superoxide anion production was
measured every 30sec, 1.5min before and 3.5min after fMLP (1m M) stimulation. The whole curves were compared using two-
way analysis of variance (p < 0.001, n = 5–6).tion,  it  was  proposed  that  LPS  priming  process
represents cellular and/or biochemical alterations that
increase the efficiency of NADPH oxidase assembly
and  the  subsequent  generation  of  superoxide
anion.14
Selective PDE4 inhibitors have been largely demon-
strated to possess in vitro and in vivo anti-inflamma-
tory activity.2,3,15 For this, they also demonstrated the
inhibition of the release of cytokines and arachidonic
acid metabolites from resident or recruited inflamma-
tory cells in airways.15 Moreover, these compounds
are able to diminish the reactive oxygen species from
various  cell  types  such  as  eosinophil,16–18 neu-
trophil,19,20 and peritoneal macrophages.21
In the present study, we observed a dose-depend-
ent inhibition by rolipram and RP 73–401 on fMLP-
induced superoxide anion production in the absence
or  presence  of  pretreatment  of  cells  with  LPS.
Maximal inhibitions were obtained at 10–6 M rolipram
and 10–7 M RP 73–401 in the absence of incubation of
the cells with LPS and 10–7 M rolipram and 10–8 M RP
73–401 in the experiments with LPS. This indicates
that RP 73–401 was more potent than rolipram in the
inhibition of superoxide anion production. This result
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FIG. 2. Effects of rolipram (10
–8 to 10
–5 M), RP 73–401 (10
–8 to 10
–5 M), or vehicle on fMLP-induced increased in superoxide
anion production (expressed in relative light units (RLU)) from peripheral blood mononuclear cells pretreated (lower panel) or
not (upper panel) with lipopolysaccharide (10m g/ml for 30min). * p < 0.05, ** p < 0.01 in comparison with non-treated (control)
cells (n = 5–6).is  consistent  with  the  study  of  Souness  et  al.,22
showing that rolipram was approximately 2600-fold
less potent than RP 73–401 against pig aortic smooth
muscle PDE4 and about 25 times less potent against
eosinophil PDE4. Interestingly, the inhibitory effects
of  RP  73–401  for  the  reduction  of  fMLP-induced
chemiluminescence is similar to that which has been
observed for the inhibition of fMLP-induced arachido-
nate release from mononuclear cells.23 In this latter
study,  we  also  proposed  that  the  PDE4  isoenzyme
inhibition represents the main mechanism, leading to
the arachidonate release from mononuclear cells, in
contrast to  the  reduction  of TNF-a release.  Such  a
mechanism of action has been previously reported for
the  inhibition  of  superoxide  anion  production  by
guinea-pig eosinophils.24 Moreover, the IC50 of the RP
73–401  for  the  inhibition  of  LPS-induced  TNF-a
release is also markedly lower (0.7nM).23 The mecha-
nism by  which RP 73–401 presents a more potent
anti-inflammatory activity when the cells are stimu-
lated with LPS is presently  unknown. One possible
explanation  is  that  additional  mechanisms  may  be
required  instead  of  the  sole  inhibition  of  PDE4
isoenzyme  and  the  increase  in  intracellular  cyclic
AMP.
We therefore analyzed the effects of a cell-perme-
able analog of cyclic AMP, db-cAMP. In our hands, db-
cAMP was able to dose-dependently inhibit the fMLP-
PDE4 inhibitors and superoxide anion
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FIG. 3. Effects of dibutyryl-cyclic AMP (db-cAMP) (10
–5 to 10
–3 M) or vehicle on fMLP-induced increased in superoxide anion
production (expressed in relative light units (RLU)) from peripheral blood mononuclear cells pretreated (lower panel) or not
(upper panel) with lipopolysaccharide. * p < 0.05, ** p < 0.01 in comparison with non-treated (control) cells (n = 5–6).induced  superoxide  anion  production,  whether  or
not  the  cells  were  incubated  with  LPS.  We  have
previously demonstrated that the inhibition of arachi-
donate  release  from  human  mononuclear  cells  by
selective  PDE4  inhibitors  is  not  associated  with  a
significant increase in intracellular cyclic AMP.4 Fur-
thermore, the fact that incubation of the cells with
cyclic AMP-dependent protein kinase (PKA) inhibitors
does  not  elicit  a  reduction  of  the  in  vitro anti-
inflammatory activities of selective PDE4 inhibitors5,6
suggested  that other  mechanisms  than  intracellular
cyclic-AMP enhancement and PKA activation must be
considered.  Interestingly,  Kambayashi  et  al.7 have
reported that rolipram can induce IL-10 release, and
that IL-10 is responsible for some inhibition of TNF-a
release. In our hands, IL-10 did not elicit significant
inhibition of fMLP-induced production of superoxide
anion  whether  or  not  the  cells  were  treated  with
fMLP.  This  result  is  consistent  with  the  study  of
Bussolati  et  al.25 demonstrating  that  IL-10  did  not
reduce  the  early  superoxide  anion  production  by
monocyte  or  polymorphonuclear  neutrophils  chal-
lenged with LPS, but was also able to enhance their
synthesis. These  results  suggest  that  the  inhibitory
activity of PDE4 inhibitors on fMLP-induced produc-
tion of superoxide anion production is mediated by
db-cAMP rather than IL-10. In contrast, the inhibitory
activity  of  PDE4  inhibitors  on  TNF-a release  and
neutrophilia in rats treated with LPS may be mediated
by IL-10 rather than by cyclic-AMP.26
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FIG. 4. Effects of interleukin 10 (IL-10) (1 and 10ng/ml) or vehicle on fMLP-induced increased in superoxide anion production
(expressed in relative light units (RLU)) from peripheral blood mononuclear cells pretreated (lower panel) or not (upper panel)
with lipopolysaccharide (n = 3).Conclusion
In  conclusion,  we  report  that incubation  with  LPS
elicits a priming  effect on the fMLP-induced super-
oxide anion production. Furthermore, the selective
PDE4 inhibitors, rolipram and RP 73–401, as well as
the cell permeable analog of cyclic-AMP (db-cAMP),
but  not  IL-10,  markedly  reduced  the  fMLP-induced
superoxide  anion  production  in  the  presence  or
absence of the incubation of the cells with LPS. These
results  suggest  that  the  inhibitory  activity  of  PDE4
inhibitors on fMLP-induced production of superoxide
anion production is mediated by db-cAMP rather than
IL-10.
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